AU2001288648A1 - Methods and compositions for inhibiting angiogenesis - Google Patents
Methods and compositions for inhibiting angiogenesisInfo
- Publication number
- AU2001288648A1 AU2001288648A1 AU2001288648A AU8864801A AU2001288648A1 AU 2001288648 A1 AU2001288648 A1 AU 2001288648A1 AU 2001288648 A AU2001288648 A AU 2001288648A AU 8864801 A AU8864801 A AU 8864801A AU 2001288648 A1 AU2001288648 A1 AU 2001288648A1
- Authority
- AU
- Australia
- Prior art keywords
- methods
- compounds
- inhibiting angiogenesis
- compositions
- endothelial cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Genetics & Genomics (AREA)
- Physical Education & Sports Medicine (AREA)
- Biochemistry (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Methods for inhibiting angiogenesis in endothelial cells and selectively inducing apoptosis in endothelial cells via compounds which binds annexin II are provided. These compounds and methods for using these compounds are useful in the treatment of diseases or disorders characterized by unwanted angiogenesis. Also provided are pharmaceutical compositions containing a compound which binds annexin II and a pharmaceutically acceptable vehicle and methods for identifying such compounds.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US22966700P | 2000-09-01 | 2000-09-01 | |
US60229667 | 2000-09-01 | ||
US27720401P | 2001-03-20 | 2001-03-20 | |
US60277204 | 2001-03-20 | ||
PCT/US2001/027310 WO2002017857A2 (en) | 2000-09-01 | 2001-09-04 | Methods and compositions for inhibiting angiogenesis |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2001288648A1 true AU2001288648A1 (en) | 2002-03-13 |
Family
ID=26923501
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2001288648A Abandoned AU2001288648A1 (en) | 2000-09-01 | 2001-09-04 | Methods and compositions for inhibiting angiogenesis |
Country Status (9)
Country | Link |
---|---|
EP (1) | EP1313504B1 (en) |
JP (1) | JP2004507482A (en) |
AT (1) | ATE346607T1 (en) |
AU (1) | AU2001288648A1 (en) |
CA (1) | CA2421503A1 (en) |
DE (1) | DE60124927T2 (en) |
DK (1) | DK1313504T3 (en) |
ES (1) | ES2272537T3 (en) |
WO (1) | WO2002017857A2 (en) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2426543C (en) | 2000-11-28 | 2007-09-18 | David M. Waisman | Anti-angiogenic polypeptides |
AU2003297181A1 (en) | 2002-12-13 | 2004-07-09 | Mediomics, Llc | Compositions and methods for inhibiting tumor growth and metastasis |
EP1670510A1 (en) * | 2003-09-24 | 2006-06-21 | Peter Krammer | Antibodies against annexins, use thereof for therapy and diagnosis. use of annexins for therapy and diagnosis. |
DE102004046540A1 (en) * | 2004-09-21 | 2006-04-06 | Eberhard-Karls-Universität Tübingen Universitätsklinikum | Annexin modulation and infection resistance |
US20060111423A1 (en) * | 2004-10-26 | 2006-05-25 | Zeligs Michael A | Use of diindolylmethane-related indoles and growth factor receptor inhibitors for the treatment of human cytomegalovirus-associated disease |
US9555074B2 (en) | 2010-10-08 | 2017-01-31 | Regents Of The University Of Minnesota | Annexin II compositions |
DK3068428T3 (en) * | 2013-11-13 | 2022-10-17 | Univ Minnesota | ANNEXIN-II VARIANT COMPOSITIONS AND METHODS |
EP3045470A1 (en) | 2015-01-15 | 2016-07-20 | Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts | Modulators of the function of the core domain of annexins, and uses thereof in autoimmune and/or cancer therapy |
ES2933825T3 (en) | 2016-06-10 | 2023-02-14 | Deutsches Krebsforschungszentrum Stiftung Des Oeffentlichen Rechts | The core domain of annexins and their uses in antigen transport and vaccination |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5051364A (en) * | 1989-02-16 | 1991-09-24 | The Salk Institute For Biological Studies | Anti-lipocortin-I and anti-lipocortin-II monoclonal antibodies |
US5639725A (en) * | 1994-04-26 | 1997-06-17 | Children's Hospital Medical Center Corp. | Angiostatin protein |
US5945403A (en) * | 1997-05-30 | 1999-08-31 | The Children's Medical Center Corporation | Angiostatin fragments and method of use |
CA2322843A1 (en) * | 1998-03-27 | 1999-09-30 | The Board Of Trustees Of The Leland Stanford, Jr. University | Hypoxia-inducible human genes, proteins, and uses thereof |
CN101386651A (en) * | 1998-08-25 | 2009-03-18 | 默克专利股份公司 | Expression and export of angiostatin and endostatin as immunofusis |
-
2001
- 2001-09-04 AT AT01968398T patent/ATE346607T1/en not_active IP Right Cessation
- 2001-09-04 ES ES01968398T patent/ES2272537T3/en not_active Expired - Lifetime
- 2001-09-04 CA CA002421503A patent/CA2421503A1/en not_active Abandoned
- 2001-09-04 AU AU2001288648A patent/AU2001288648A1/en not_active Abandoned
- 2001-09-04 EP EP01968398A patent/EP1313504B1/en not_active Expired - Lifetime
- 2001-09-04 DE DE60124927T patent/DE60124927T2/en not_active Expired - Fee Related
- 2001-09-04 DK DK01968398T patent/DK1313504T3/en active
- 2001-09-04 JP JP2002522832A patent/JP2004507482A/en active Pending
- 2001-09-04 WO PCT/US2001/027310 patent/WO2002017857A2/en active IP Right Grant
Also Published As
Publication number | Publication date |
---|---|
EP1313504A2 (en) | 2003-05-28 |
ES2272537T3 (en) | 2007-05-01 |
ATE346607T1 (en) | 2006-12-15 |
WO2002017857A3 (en) | 2002-06-13 |
DE60124927T2 (en) | 2007-09-20 |
DE60124927D1 (en) | 2007-01-11 |
JP2004507482A (en) | 2004-03-11 |
EP1313504B1 (en) | 2006-11-29 |
WO2002017857A2 (en) | 2002-03-07 |
CA2421503A1 (en) | 2002-03-07 |
DK1313504T3 (en) | 2007-02-26 |
EP1313504A4 (en) | 2004-06-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL150742A0 (en) | Pyridopyrimidinone derivatives for the treatment of neurodegenerative disease | |
WO2002078766A3 (en) | Combination therapy | |
PL373903A1 (en) | A combination of an nmda-antagonist and acetylcholine esterase inhibitors for the treatment of alzheimer's disease | |
BG101841A (en) | Cellular adhesion inhibitors | |
AU2002225772A1 (en) | Therapeutic agents and methods of use thereof for treating an amyloidogenic disease | |
ZA200109073B (en) | Compositions for treatment of disorders of the oesophagus. | |
WO2003106381A3 (en) | Human adam-10 inhibitors | |
BRPI0410049A (en) | compound or a pharmaceutically acceptable salt or stereoisomer thereof, use of a compound, pharmaceutical composition, and pharmaceutical kit | |
MY124786A (en) | Bis-arylsulfones | |
GB0002336D0 (en) | Medicaments | |
AU1774097A (en) | Pharmaceutical compositions for the treatment of rhinitis | |
AU2000258650A1 (en) | 2-piperidone compounds for the treatment of cancer | |
AU2001288648A1 (en) | Methods and compositions for inhibiting angiogenesis | |
WO2002018341A3 (en) | Quinoline- (c=o) - (di-, tri- and tetrapeptide) derivatives as caspase inhibitors | |
CO5190674A1 (en) | TREATMENT OF NEUROTIC DISORDERS NEUROTIC DISORDERS | |
AU4179399A (en) | Use of nmda antagonists and/or sodium channel antagonists for the treatment of inflammatory disorders | |
IL153831A (en) | Pharmaceutical composition for therapy of neurodegenerative disease of the brain | |
GB9907571D0 (en) | Compounds | |
DE69917005D1 (en) | SUBSTITUTED PYRROLOBENZIMIDAZOLE DERIVATIVES FOR ANTI-INFLAMMATION | |
AU2670600A (en) | Pharmaceutical composition containing desoxypeganine for the treatment of nicotine dependence | |
DE69715173D1 (en) | Bisarylcyclobutenderivate als cyclooxygenasehemmer | |
AU7216498A (en) | Inhibitors of the urokinase receptor | |
AU3004000A (en) | Methods for the treatment of apolipoprotein e related diseases | |
JO2199B1 (en) | Substituted pyrroles | |
WO2004050014A3 (en) | Seterocyclic quinones as pharmaceutical agents |